BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing
globenewswire.com
news
2022-10-21 00:00:00

BriaCell has successfully completed its Phase I safety and tolerability evaluation of Bria-IMT™ in combination with Incyte's retifanlimab in advanced breast cancer. The combination treatment showed a favorable safety profile in 12 patients. Phase II efficacy portion of the study, under FDA's fast track designation, now underway with survival data and clinical benefit being compiled. PHILADELPHIA and VANCOUVER, British Columbia, Oct. 21, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ('BriaCell' or the 'Company'), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce the completion of the Phase I part of the clinical trial of its lead candidate, Bria-IMT™, in combination with Incyte's PD-1 inhibitor, retifanlimab, in advanced breast cancer.
